Literature DB >> 1674900

Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice.

M Tominaga1, A Matsumori, I Okada, T Yamada, C Kawai.   

Abstract

BACKGROUND: The effects of carteolol, a nonselective beta-adrenergic receptor blocker with intrinsic sympathomimetic activity, were compared with those of metoprolol in a murine model of viral myocarditis and dilated cardiomyopathy caused by encephalomyocarditis virus. METHODS AND
RESULTS: In the acute experiment, BALB/c and DBA/2 mice were inoculated with encephalomyocarditis virus. BALB/c mice were then given carteolol at 1 (n = 10), 10 (n = 10), 30 (n = 11), or 100 mg/kg (n = 9) daily, and DBA/2 mice were given carteolol at 1 (n = 9) or 10 mg/kg (n = 9) daily starting the day of inoculation. Controls were given distilled water (n = 23 for BALB/c mice and n = 8 for DBA/2 mice). BALB/c mice were killed on day 7, and DBA/2 mice were killed on day 14. In the subacute experiment, DBA/2 mice were inoculated with the virus and then given carteolol at 1 (n = 12) or 10 mg/kg (n = 16), or distilled water (n = 27) daily, starting on day 14. Mice were killed on day 28. Virus replication, murine survival, heart weight to body weight ratio, and histopathological findings were similar in each group in the acute and subacute experiments. In the chronic experiment, DBA/2 mice were inoculated with the virus and were then given carteolol at 1 (n = 13) or 10 mg/kg (n = 9), metoprolol at 30 mg/kg (n = 9), or distilled water (n = 31) daily, starting on day 14. Mice were killed on day 104. Heart weight to body weight ratio and histopathological scores were significantly lower in mice given carteolol than in the infected control group. Furthermore, left ventricular cavity dimension, left ventricular wall thickness, and myocardial fiber diameter of the left ventricle were significantly reduced in mice given carteolol compared with the control group. Metoprolol did not cause any significant changes compared with the control group.
CONCLUSIONS: This study suggests that carteolol prevents the development of myocardial lesions similar to those in dilated cardiomyopathy after myocarditis in the chronic stage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674900     DOI: 10.1161/01.cir.83.6.2021

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Apoptosis in congestive heart failure induced by viral myocarditis in mice.

Authors:  T Yamada; A Matsumori; W Z Wang; N Ohashi; K Shiota; S Sasayama
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

Review 2.  Diagnosis and management of pediatric myocarditis.

Authors:  Desmond Bohn; Lee Benson
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

Review 4.  Pharmacotherapy of dilated cardiomyopathy: current status and future directions.

Authors:  C Kawai
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

5.  Cardioprotective effects of carvedilol on acute autoimmune myocarditis.

Authors:  Zuyi Yuan; Keisuke Shioji; Masaomi Nimata; Chiharu Kishimoto
Journal:  Mol Cell Biochem       Date:  2004-04       Impact factor: 3.396

Review 6.  Use of beta-adrenoceptor blockers in patients with congestive heart failure.

Authors:  V Panfilov; I Wahlqvist; G Olsson
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

7.  Low-dose combination therapy with metoprolol and captopril for congestive heart failure in mice.

Authors:  T Kanda; M Inoue; T Suzuki; K Murata
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

Review 8.  Innovative drug treatments for viral and autoimmune myocarditis.

Authors:  S Anandasabapathy; W H Frishman
Journal:  J Clin Pharmacol       Date:  1998-04       Impact factor: 3.126

9.  Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.

Authors:  Chukwuka C Okafor; Cynthia Perreault-Micale; Roger J Hajjar; Djamel Lebeche; Klara Skiroman; George Jabbour; Angelia A Doye; Michael X Lee; Nancy Laste; Judith K Gwathmey
Journal:  BMC Physiol       Date:  2003-07-21

Review 10.  SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications.

Authors:  Ossama K Abou Hassan; Calvin C Sheng; Tom Kai Ming Wang; Paul C Cremer
Journal:  Curr Cardiol Rep       Date:  2021-08-03       Impact factor: 2.931

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.